BSX logo

Boston Scientific Corporation Stock Price

NYSE:BSX Community·US$110.4b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 123 Fair Values set on narratives written by author

BSX Share Price Performance

US$75.15
-25.57 (-25.39%)
US$104.75
Fair Value
US$75.15
-25.57 (-25.39%)
28.3% undervalued intrinsic discount
US$104.75
Fair Value
Price US$75.15
AnalystConsensusTarget US$104.75

BSX Community Narratives

AnalystConsensusTarget·
Fair Value US$104.75 28.3% undervalued intrinsic discount

Future Growth Plans And Acquisitions Will Drive Broader Market Expansion

1users have liked this narrative
0users have commented on this narrative
49users have followed this narrative
US$104.75
28.3% undervalued intrinsic discount
Revenue
10.48% p.a.
Profit Margin
19.61%
Future PE
37.1x
Price in 2029
US$131.58

Trending Discussion

Updated Narratives

BSX logo

BSX: Organizational Changes Should Support Rebound As 2026 Patterns Normalize

Fair Value: US$104.75 28.3% undervalued intrinsic discount
49 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Solid track record with excellent balance sheet.

0 Risks
4 Rewards

Boston Scientific Corporation Key Details

US$20.1b

Revenue

US$6.3b

Cost of Revenue

US$13.8b

Gross Profit

US$10.9b

Other Expenses

US$2.9b

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
1.95
68.78%
14.44%
46.2%
View Full Analysis

About BSX

Founded
1979
Employees
59000
CEO
Michael Mahoney
WebsiteView website
www.bostonscientific.com

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, radiofrequency ablation, and intraosseous nerve ablation and deep brain stimulation systems. The company also provides technologies for diagnosing and treating a range of diseases and abnormalities of the heart; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, it offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose and treat forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Recent BSX News & Updates

Recent updates

No updates